Är genterapi medierad av adenoassocierat virus en effektiv och säker behandling mot hemofili A och B ur ett långsiktigt perspektiv? : En systematisk litteraturstudie

Är genterapi medierad av adenoassocierat virus en effektiv och säker behandling mot hemofili A och B ur ett långsiktigt perspektiv? : En systematisk litteraturstudie

Bakgrund - Hemofili A och B är X-kromosombundna blödarsjukdomar, som beror på genetiska avvikelser i de gener som kodar för koagulationsfaktor VIII respektive IX. I dagsläget förlitar sig hemofilipatienter på kontinuerliga intravenösa injektioner med faktorkoncentrat, för att förhindra att...

Full description

Bibliographic Details
Main Author:	Landin, Linnéa
Format:	Others
Language:	Swedish
Published:	Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB) 2020
Subjects:	Hemophilia hemophilia A hemophilia B factor VIII factor IX gene therapy adeno- associated virus AAV Hemofili hemofili A hemofili B faktor VIII faktor IX genterapi adenoassocierat virus Biological Sciences Biologiska vetenskaper Medical Biotechnology Medicinsk bioteknik Genetics Genetik Hematology Hematologi Biomedical Laboratory Science/Technology Biomedicinsk laboratorievetenskap/teknologi
Online Access:	http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-98996

Similar Items

Hur effektiv och säker är rekombinant och renad plasma faktor VIII-behandling för hemofili A patienter?
by: Youssef, Dima
Published: (2013)

A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in north eastern part of India
by: Sandip Kumar, et al.
Published: (2019-01-01)

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
by: Anshu Shrestha, et al.
Published: (2021-01-01)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
by: Jacky K. Yu, et al.
Published: (2019-07-01)

Perioperative Management of Patients with Hemophilia during Spinal Surgery
by: Kazuyoshi Kobayashi, et al.
Published: (2018-06-01)

Importancia del diagnóstico de portadoras en familias con antecedentes de hemofilia
by: Kalia Lavaut Sánchez

“Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A Study of 276 Patients in Western India
by: Sangita Darshan Shah, et al.
Published: (2019-01-01)

Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
by: David M. Markusic, et al.
Published: (2017-05-01)

Livet som blödarsjuk : Upplevelser av att leva med hemofili A, hemofili B eller von Willebrands sjukdom
by: Faberling, Emma, et al.
Published: (2014)

Molecular diagnosis of hemophilia A and B. Report of five families from Costa Rica
by: Lizbeth Salazar-Sánchez, et al.
Published: (2004-09-01)

IMPORTANŢA EXAMENULUI ECOGRAFIC ÎN DIAGNOSTICUL ŞI TRATAMENTUL AFECŢIUNILOR MUSCULO-SCHELETALE DIN HEMOFILIA A
by: Adriana Diaconu, et al.
Published: (2018-09-01)

Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette
by: Sandeep R.P. Kumar, et al.
Published: (2021-12-01)

Hemofili och livskvalitet, erfarenheter och upplevelser hos män av att leva med en kronisk genetisk sjukdom - en semistrukturerad intervjustudie
by: Uhrfeldt, Charlotte, et al.
Published: (2010)

Hemofilia II. Aspectos moleculares y de genética poblacional Hemophilia II. Molecular and population genetics
by: Dunia Castillo-González
Published: (2012-06-01)

The odds and implications of coinheritance of hemophilia A and B
by: Corinne Karch, et al.
Published: (2020-07-01)

New developments in the management of moderate-to-severe hemophilia B
by: Nazeef M, et al.
Published: (2016-04-01)

Murine leukemia virus-derived retroviral vector has differential integration patterns in human cell lines used to produce recombinant factor VIII
by: Marcela Cristina Correa de Freitas, et al.
Published: (2014-06-01)

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
by: Beth Boulden Warren, et al.
Published: (2021-07-01)

Purificación del factor IX recombinante expresado en leche de cerdas transgénicas Purification of recombinant factor IX expressed in milk of transgenic sows
by: Armando Cádiz Lahens, et al.
Published: (2006-08-01)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
by: Cecilia Augustsson, et al.
Published: (2020-10-01)

Tratamiento de la infección en la hepatitis C y la hemofilia Hepatitis C related with hemophilia. Treatment of infection
by: René A Rivero Jiménez
Published: (2009-04-01)

Prothrombotic risk mutations and polymorphisms in patients with hemophilia A – a preliminary study / Polimorfismele și mutațiile cu risc protrombotic la pacienții cu hemofilie A - studiu preliminar
by: Boeriu Estera, et al.
Published: (2015-03-01)

Genetic variation of rs438601 marker in the Iranian Population: An informative marker for molecular diagnosis of hemophilia B
by: P Dorri, et al.
Published: (2014-12-01)

Evaluation of efficacy of twice-weekly prophylactic treatment with BeneFIX® (recombinant factor IX) followed by once weekly in children with severe hemophilia B: Six-year data from a local registry
by: Rafal Raad Al-Janabi, et al.
Published: (2021-01-01)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
by: Lieuw K
Published: (2017-06-01)

Şiddetli Hemofili A Hastalarında Sınırlanmış Eklem Açıklığı ile İlişkili Atrofik Kaslarda Su İçi Egzersizlerin Etkisi: Bir Pilot Çalışma
by: Çiğdem ÖZDEMİR, et al.
Published: (2014-07-01)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
by: Byung Suk Moon, et al.
Published: (2013-07-01)

A case of subdural hematoma with a medical history of hemophilia a and a review of related literature
by: Yi Zhao, et al.
Published: (2018-05-01)

Clinical practice of personalized prophylaxis in hemophilia: Illustrations of experiences and benefits from two continents
by: Shannon Jackson, et al.
Published: (2019-04-01)

MYOCARDIAL INFARCTION AND HEMOPHILIA
by: A. S. Galyavich, et al.
Published: (2016-03-01)

Clinical and Laboratory Approaches to Hemophilia A
by: Hassan Mansouritorghabeh
Published: (2015-05-01)

Educational needs of hematologists and laboratory professionals regarding factor activity assays
by: Adcock DM, et al.
Published: (2018-04-01)

Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model
by: Lorenzo Pradelli, et al.
Published: (2018-01-01)

Production of specific polyclonal antibodies anti-human factor IX
by: Daniel Gonçalves Chaves, et al.
Published: (2006-07-01)

Defining the molecular pathology and consequent phenotypes in Egyptian HB patients
by: Ghada Y. El-Kamah, et al.
Published: (2021-05-01)

Surgery-associated acquired hemophilia A: a report of 2 cases and review of literature
by: Umar Zeb Khan, et al.
Published: (2020-09-01)

Perioperative management of patient with hemophilia a underwent orthopedic surgery
by: Tjokorda G A Senapathi, et al.
Published: (2017-01-01)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
by: Shuichi Okamoto, et al.
Published: (2019-10-01)

[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]
by: Lucia Sara D'Angiolella, et al.
Published: (2017-02-01)

Giant Intramural Hematoma of the Colon in Acquired Factor VIII Inhibitor
by: Joana Figueiredo, et al.
Published: (2019-09-01)